{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T13:48:24Z","timestamp":1771595304764,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":65,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.euroneuro.2022.01.007","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T02:29:19Z","timestamp":1642991359000},"page":"92-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9925-7866","authenticated-orcid":false,"given":"Risha","family":"Govind","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8876-4595","authenticated-orcid":false,"given":"Daniela Fonseca","family":"de Freitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1801-1635","authenticated-orcid":false,"given":"Mizanur","family":"Khondoker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6899-8319","authenticated-orcid":false,"given":"James T.","family":"Teo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4453-244X","authenticated-orcid":false,"given":"Richard D.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6754-1018","authenticated-orcid":false,"given":"James H.","family":"MacCabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.euroneuro.2022.01.007_bib0001","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: A comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2022.01.007_bib0002","first-page":"450","article-title":"\u2018Clozapine in the time of COVID-19\u2019, Clinical Psychopharmacology and Neuroscience","volume":"18","author":"Boland","year":"2020","journal-title":"Korean College of Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2022.01.007_bib0003","article-title":"Clozapine prescribing in COVID-19 positive medical inpatients: a case series","volume":"10","author":"Butler","year":"2020"},{"key":"10.1016\/j.euroneuro.2022.01.007_bib0004","article-title":"Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study","volume":"139","author":"Cho","year":"2018"},{"issue":"4","key":"10.1016\/j.euroneuro.2022.01.007_bib0005","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jpsychires.2012.12.007","article-title":"The incidence and all-cause mortality of pneumonia in patients with schizophrenia: A nine-year follow-up study","volume":"47","author":"Chou","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2022.01.007_bib0006","unstructured":"CRIS NLP Applications Library (2020) CRIS natural language processing, v1.1. Available at: https:\/\/www.maudsleybrc.nihr.ac.uk\/facilities\/clinical-record-interactive-search-cris\/cris-natural-language-processing\/."},{"key":"10.1016\/j.euroneuro.2022.01.007_bib0007","volume":"at","year":"2020"},{"key":"10.1016\/j.euroneuro.2022.01.007_bib0008","first-page":"1","article-title":"Clozapine treatment and risk of COVID-19 infection: retrospective cohort study","author":"Govind","year":"2020","journal-title":"Br. J. Psychiatry R. Coll. Psychiatr."},{"issue":"4","key":"10.1016\/j.euroneuro.2022.01.007_bib0009","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/eb-2013-101441","article-title":"Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia","volume":"16","author":"Haddad","year":"2013","journal-title":"Evid. Based Ment. Health"},{"key":"10.1016\/j.euroneuro.2022.01.007_bib0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1192\/bjp.bp.117.202606","article-title":"Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000-2014","author":"Hayes","year":"2017","journal-title":"Br. J. Psychiatry R. Coll. Psychiatr."},{"issue":"3","key":"10.1016\/j.euroneuro.2022.01.007_bib0011","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/schbul\/sbu120","article-title":"The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders","volume":"41","author":"Hayes","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2022.01.007_bib0012","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.schres.2018.04.009","article-title":"Premature mortality among people with severe mental illness - New evidence from linked primary care data","volume":"199","author":"John","year":"2018","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.euroneuro.2022.01.007_bib0013","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1177\/0269881118817387","article-title":"Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine","volume":"33","author":"Kesserwani","year":"2019","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.euroneuro.2022.01.007_bib0014","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/schbul\/sbr202","article-title":"Second-generation antipsychotic medications and risk of pneumonia in schizophrenia","volume":"39","author":"Kuo","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.euroneuro.2022.01.007_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/schbul\/sbz093","article-title":"Data from the World Health Organization\u2019s pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions","volume":"46","author":"De Leon","year":"2020","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.euroneuro.2022.01.007_bib0016","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/wps.20384","article-title":"Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas","volume":"16","author":"Liu","year":"2017","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.01.007_bib0017","series-title":"CNS Drugs","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects","author":"Newcomer","year":"2005"},{"issue":"3","key":"10.1016\/j.euroneuro.2022.01.007_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-008721","article-title":"Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case Register: current status and recent enhancement of an Electronic Mental Health Record-derived data resource","volume":"6","author":"Perera","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.euroneuro.2022.01.007_bib0019","unstructured":"Public Health England (2020) PHE reporting of COVID-19 deaths: technical summary, 12 August 2020. Available at: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/916035\/RA_Technical_Summary_-_PHE_Data_Series_COVID_19_Deaths_20200812.pdf."},{"issue":"2","key":"10.1016\/j.euroneuro.2022.01.007_bib0020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/thoraxjnl-2012-202480","article-title":"\u2018Risk of pneumonia and pneumococcal disease in people with severe mental illness: English record linkage studies\u2019","volume":"68","author":"Seminog","year":"2013","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.euroneuro.2022.01.007_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-021187","article-title":"Risk of pleural empyema in patients with schizophrenia: A nationwide propensity-matched cohort study in Taiwan","volume":"8","author":"Shen","year":"2018","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.euroneuro.2022.01.007_bib0022","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"Br. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2022.01.007_bib0023","first-page":"2","article-title":"Consensus statement on the use of clozapine during the COVID-19 pandemic","volume":"45","author":"Siskind","year":"2020","journal-title":"J. Psychiat. Neurosci. JPN"},{"issue":"1","key":"10.1016\/j.euroneuro.2022.01.007_bib0024","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1471-244X-9-51","article-title":"The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data","volume":"9","author":"Stewart","year":"2009","journal-title":"BMC Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2022.01.007_bib0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/YIC.0000000000000162","article-title":"Clozapine usage increases the incidence of pneumonia compared with risperidone and the general population: A retrospective comparison of clozapine, risperidone, and the general population in a single hospital over 25 months","volume":"32","author":"Stoecker","year":"2017","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.01.007_bib0026","series-title":"Pathology Research and Practice","article-title":"Pathologic features of COVID-19: A concise review","author":"Tabary","year":"2020"},{"key":"10.1016\/j.euroneuro.2022.01.007_bib0027","series-title":"Schizophrenia Bulletin","first-page":"315","article-title":"Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years","author":"Vermeulen","year":"2019"},{"key":"10.1016\/j.euroneuro.2022.01.007_bib0028","series-title":"European Neuropsychopharmacology","article-title":"The impact of the Covid-19 pandemic on patients with schizophrenia","author":"Vita","year":"2021"},{"issue":"10","key":"10.1016\/j.euroneuro.2022.01.007_bib0029","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1176\/appi.ajp.2017.16091097","article-title":"Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia","volume":"174","author":"Wimberley","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.01.007_bib0030","series-title":"Physical status: the Use and Interpretation of anthropometry. Report of a WHO Expert Committee","year":"1995"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X22000153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X22000153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:02:12Z","timestamp":1760378532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X22000153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":30,"alternative-id":["S0924977X22000153"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2022.01.007","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2022.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}